What's in a Domain? The Role of NOTCH3 EGFr Domains in CADASIL Disease Severity
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Twenty-five years ago, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) was considered a rare, severe genetic small vessel disease leading to recurrent stroke and vascular dementia in midadulthood. Although it is now abundantly clear that CADASIL is at least as prevalent as more well-known genetic causes of dementia, such as Huntington disease and early-onset Alzheimer dementia, CADASIL remains stubbornly unknown, overlooked, and underrecognized. This may be partially attributable to the variable disease severity and presentation, as well as the clinical and neuroimaging overlap with sporadic causes of small vessel disease. In 2016, it was discovered that characteristic CADASIL-causing cysteine-altering NOTCH3 variants (NOTCH3cys) are unexpectedly frequent in the general population (1:300).1 This was a game changer in our understanding of CADASIL disease variability, leading to the identification of NOTCH3cys variant position as the most important CADASIL disease modifier. NOTCH3cys variants located in one of the first 6 EGFr domains of the NOTCH3 protein (EGFr 1–6) are frequent in CADASIL cohorts, rare in the population, and are associated with severe disease. Conversely, EGFr 7–34 variants are less frequent in CADASIL cohorts, highly frequent in the population, and are associated with a very broad disease spectrum ranging from “classical” severe CADASIL to a very mild small vessel disease and even nonpenetrance.2-7
Footnotes
* All authors contributed equally.
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
See page 185
- Received March 11, 2022.
- Accepted in final form April 1, 2022.
- © 2022 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.